Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31

Cingulate Inc.

Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.
Cash and cash equivalents $25.9M at Mar 31, up $14.9M from Dec 31, extending runway into 2027.
FDA review of CTx-1301 NDA ongoing; PDUFA target action date remains May 31, 2026.
Commercial readiness advanced with AI-driven tools and IQVIA sales force agreement for potential launch.
R&D expenses decreased 1.8% to $2.2M as clinical studies concluded, partly offset by regulatory and CMC activities.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cingulate Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $9.3 million for the three months ended March 31, 2026.

Period: the quarter ended March 31, 2026
Net income: Net loss was $9.3 million for the three months ended March 31, 2026
Result: reported results

Exact text from the filing

Cingulate Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing a business update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.